Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®
Evoke Pharma announced a significant achievement with the U.S. Patent and Trademark Office granting a Notice of Allowance for its nasal spray Gimoti (metoclopramide), aimed at treating gastroparesis. The patent, covering the method of use for this innovative delivery system, extends protection until at least 2029. Gimoti, which received FDA approval in June 2020, offers a critical option for diabetic patients struggling with oral medication absorption. This development enhances Evoke's intellectual property portfolio and marketing strategy.
- USPTO granted a Notice of Allowance for Gimoti nasal spray patent, extending IP protection to 2029.
- Gimoti is the first FDA-approved medication for gastroparesis available in nasal spray form, improving treatment options.
- None.
New patent expands intellectual property protection for nasal delivery of metoclopramide
SOLANA BEACH, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance to Evoke for U.S. Application No. 16/181,841 for Gimoti® (metoclopramide) nasal spray. When granted, the patent will cover methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis. The patent, entitled “Nasal Formulations of Metoclopramide,” carries a patent term to at least 2029. Gimoti is Evoke’s nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis. The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Gimoti in June 2020. This new patent covers Gimoti for gastroparesis and will be listable in FDA’s Orange Book.
“We are pleased with this additional USPTO determination that Gimoti is innovative and novel. We believe Gimoti provides an important option for treating diabetic gastroparesis patients with nasal delivery, especially as the disease can cause patients to experience delayed digestion of oral medications,” commented Dave Gonyer, President and CEO. “The issuance of this Notice of Allowance strengthens the intellectual property protection for Gimoti and will provide another Orange Book-listable patent and a significant addition to our intellectual property estate and overall marketing strategy for Gimoti.”
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Evoke’s current beliefs and expectations. These forward-looking statements include statements regarding Evoke’s expectations on the scope of any patent protection. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated Evoke’s ability to obtain and maintain intellectual property protection for GIMOTI and other risks and uncertainties inherent in Evoke’s business, including those described in Evoke’s periodic filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Contacts:
The Ruth Group
Christine Petraglia / James Salierno
Tel: 917-633-8980 / 973-255-8361
cpetraglia@theruthgroup.com / jsalierno@theruthgroup.com
Media Contact:
The Ruth Group
Annika Parrish
Tel: 720-412-9042
aparrish@theruthgroup.com
FAQ
What is the purpose of the Gimoti nasal spray?
When was Gimoti approved by the FDA?
What does the new patent for Gimoti cover?
How long is the patent for Gimoti effective?
Why is the patent allowance important for Evoke?
